2. Disease Areas
  3. Urogenital Disease
  4. Urogenital Cancer

Urogenital Cancer

Genitourinary cancers encompass malignancies affecting the urinary system in both men and women, as well as male reproductive organs. In men, these include prostate, bladder, kidney, adrenal gland, urethra, penile, and testicular cancers. In women, cancers of the reproductive organs are classified separately as gynecologic cancers. These cancers arise from abnormal cell growth in the genitourinary tract, including the kidneys, bladder, ureters, urethra, prostate, testes, and penis.

References:

 

Urogenital Cancer (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-17386
    Rosiglitazone 122320-73-4 99.94%
    Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC50: 60 nM, Kd: 40 nM). Rosiglitazone is an TRPC5 activator (EC50: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer.
    Rosiglitazone